Small Fiber Neuropathy

Neurology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Octapharma
OctapharmaAustria - Vienna
1 program
1
Panzyga IVIGPhase 21 trial
Active Trials
NCT04153422Recruiting20Est. Feb 2028
VP
1 program
1
VX-150Phase 21 trial
Active Trials
NCT03304522Completed89Est. Nov 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
OctapharmaPanzyga IVIG
Vertex PharmaceuticalsVX-150

Clinical Trials (2)

Total enrollment: 109 patients across 2 trials

IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

Start: Dec 2023Est. completion: Feb 202820 patients
Phase 2Recruiting

A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy

Start: Sep 2017Est. completion: Nov 201889 patients
Phase 2Completed

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 109 patients
2 companies competing in this space